Building Upon a Heritage of Innovation in Biosimilars
Building on our strengths in developing biologics, Pfizer has a healthy portfolio of potential biosimilar candidates in mid- to late-stage development and we are confident about our ability to bring these important medicines to the patients who need them. Our development portfolio includes proposed biosimilars to: adalimumab (Humira®), bevacizumab (Avastin®), rituximab (Rituxan®/MabThera®), trastuzumab (Herceptin®) and pegfilgrastim (Neulasta®).
Recent milestones include Biologics License Application (BLA) approvals for Nivestym™ (filgrastim) and Retacrit™ (epoetin alfa-epbx), as well as Marketing Authorization Application (MAA) approval for Trazimera™ (trastuzumab). In addition, BLAs for Trazimera, Zirabev™ (bevacizumab), and rituximab, and MAAs for adalimumab, Zirabev™ (bevacizumab), and rituximab have been accepted for review.
Ian Read: Contributions to Improving Human Health
Albert Bourla: Breakthroughs that Change Patients' Lives
Ushering in a New Era of Pfizer R&D Productivity
Advancing Our Leading JAK Science
Overcoming Therapy-Resistant Disease
Tackling Respiratory Syncytial Virus (RSV) Through Breakthrough Science and Technology
Catalyzing Innovations in Global Health
Contributing to the UN Sustainable Development Goals
Supporting Digital Health Start-Ups
Improving the Health of Women and Their Families